DexCom, Inc. (DXCM)

Glucose monitor maker, 11,100 employees. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 12, 2026. Ranked 72 of the 95 Healthcare companies read so far, by the share within reach now.

Dexcom states approximately 11,100 employees around the globe at December 31, 2025, 11,000 of them full-time, making continuous glucose monitoring systems with no count by kind of work or country, so one pattern takes the whole workforce at medical equipment by description (c).

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 31% at the end of 2027, 36% at the end of 2028, 38% at the end of 2030. By the patterns, the work is about 38% desk work, 16% people work and 46% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 35% becomes checking a model's work and 6% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

11,100 employees as of December 31, 2025 (stated). The filing counts no employees by country; the data service's geography table (non-U.S. 100%) is not usable.

The filing: “As of December 31, 2025, we have approximately 11,100 employees around the globe, including 11,000 full-time employees.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 11,100 employees, 11,000 of them full-time; remote and hybrid work for roles that allow it; the count rose from 9,500 in 2023 and 5,500 in 2020.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Medical Equipment and Supplies Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Abbott Laboratories (ABT, 115,000 employees)18% now, 35% by 2028
• Becton, Dickinson and Company (BDX, 72,000 employees)19% now, 36% by 2028
• Boston Scientific Corporation (BSX, 59,000 employees)19% now, 42% by 2028
• Stryker Corporation (SYK, 56,000 employees)19% now, 39% by 2028
• Baxter International Inc. (BAX, 37,500 employees)19% now, 37% by 2028
• Align Technology, Inc. (ALGN, 20,290 employees)19% now, 36% by 2028
• Solventum Corporation (SOLV, 20,000 employees)20% now, 43% by 2028
• STERIS plc (STE, 17,937 employees)22% now, 39% by 2028

What the filing says about AI

20 sentences in the filing name AI. The filing says it intends to apply predictive modeling and machine learning to CGM patient data for interactive insights, and names the EU AI Act's treatment of AI-enabled medical devices among its regulatory matters.

• “We intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior.”
• “These changes could also reduce the number of AI-enabled medical devices classified as "high-risk" under the EU AI Act (Regulation (EU) 2024/1689); Clarification of the interplay with the AI Act, providing that most requirements applicable to high-risk AI systems under the AI Act would not apply to AI-based medical devices, in order to avoid regulatory overlaps; Extension of CE Certificate vali...”
• “In addition to the proposed revision of the MDR, these include the AI Act (Regulation (EU) 2024/1689), the Data Act (Regulation (EU) 2023/2854), the Health Data Space Regulation (Regulation (EU) 2025/327), the Regulation on Health Technology Assessment (Regulation (EU) 2021/2282), the Battery Regulation (Regulation (EU) 2023/1542), and the Network and Information Security Directive (NIS 2) (Dir...”
• “In particular, the Digital Omnibus Package consists of two legislative proposals: A first proposal introducing amendments to several pieces of legislation, including Regulation (EU) 2016/679 (GDPR), the ePrivacy Directive (Directive 2002/58/EC), the NIS2 Directive and other instruments relating to cybersecurity (DORA, CER, eIDAS), and the Data Act; and A second proposal aimed at amending the AI...”
• “Moreover, we are subject to various operational, compliance, and reputational risks associated with our adoption and utilization of AI technologies, including inaccurate or unpredictable outputs, such as errors or hallucinations, that may impair decision‑making, disrupt operations, or expose sensitive information.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20212median 0
• Fiscal 20222median 0
• Fiscal 20232median 1
• Fiscal 202412median 4
• Fiscal 202520median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• No count by kind of work: the one pattern is by description (c).
• The U.S. share is not stated.

Source: the company's annual report on EDGAR, accession 0001093557-26-000027, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.